Unbiased analysis of knee cartilage thickness change over three years after sprifermin vs. placebo treatment - A post-hoc analysis from the phase 2B FORWARD study.

Felix Eckstein^1,2,3, Susanne Maschek^1,2,3, Wolfgang Wirth^1,2,3, Christoph Ladel⁴, Asger Reinstrup Bihlet⁵, Chris Knight⁶, Kenneth Somberg⁶, Luping Zhao⁶

¹Research Program for Musculoskeletal Imaging, Center for Anatomy & Cell Biology, Paracelsus Medical University (PMU), Salzburg, Austria.

²Ludwig Boltzmann Institute for Arthritis and Rehabilitation (LBIAR), Paracelsus Medical University (PMU), Salzburg, Austria.

³Chondrometrics GmbH, Freilassing, Germany.

⁴CHL4special Consulting, Darmstadt, Germany.

⁵NBCD A/S, Copenhagen, Denmark.

⁶Formation Bio, New York, NY, United States.

PubMed PMC DOI PDF

Abstract

OBJECTIVE: Post-treatment cartilage morphometry in the FORWARD study was performed without blinding to MRI acquisition order, involving potential reader bias. Here we obtained unbiased estimates of cartilage change post-treatment, reading year (Y)2 and Y5 MRIs with blinding to time point. We studied whether post-treatment cartilage thickness change differed between sprifermin- and placebo-treated…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.